These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38533651)

  • 1. Toward a Functional Cure for Hepatitis B.
    Lok ASF
    Gut Liver; 2024 Jul; 18(4):593-601. PubMed ID: 38533651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What will it take to cure hepatitis B?
    Jeng WJ; Lok ASF
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy.
    Bazinet M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Krawczyk A; Vaillant A
    Gastroenterology; 2020 Jun; 158(8):2180-2194. PubMed ID: 32147484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus.
    Durantel D; Zoulim F
    J Hepatol; 2016 Apr; 64(1 Suppl):S117-S131. PubMed ID: 27084032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    Wong GLH; Gane E; Lok ASF
    J Hepatol; 2022 Jun; 76(6):1249-1262. PubMed ID: 35589248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.
    Zhao Q; Liu H; Tang L; Wang F; Tolufashe G; Chang J; Guo JT
    Antiviral Res; 2024 Jan; 221():105782. PubMed ID: 38110058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New Potential Therapies for Chronic Hepatitis B].
    Yoo SH; Kwon JH
    Korean J Gastroenterol; 2019 Nov; 74(5):267-273. PubMed ID: 31765555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, multicentre, randomised controlled trial comparing the seroclearance of HBsAg between combination therapy of peg-interferon alpha and tenofovir with tenofovir monotherapy in nucleos(t)ide analogue-experienced patients with HBV-related liver fibrosis: a study protocol.
    Zhu S; Wu L; Mei Y; Liu Z; Lin L; Yuan J; Li J; Li X; Peng L
    BMJ Open; 2021 Oct; 11(10):e049104. PubMed ID: 34697111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we cure hepatitis B virus with novel direct-acting antivirals?
    Martinez MG; Villeret F; Testoni B; Zoulim F
    Liver Int; 2020 Feb; 40 Suppl 1():27-34. PubMed ID: 32077597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha.
    Chen H; Sun J; Zhou B; Xie Q; Liang X; Fan R; Conran C; Xu J; Ji Y; Zhang X; Sun L; Jia J; Wang G; Hou J; Jiang DK
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):196-204.e8. PubMed ID: 31042581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Hepatitis B Infection: A Review.
    Tang LSY; Covert E; Wilson E; Kottilil S
    JAMA; 2018 May; 319(17):1802-1813. PubMed ID: 29715359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis B: what should be the goal for new therapies?
    Block TM; Gish R; Guo H; Mehta A; Cuconati A; Thomas London W; Guo JT
    Antiviral Res; 2013 Apr; 98(1):27-34. PubMed ID: 23391846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B cure: From discovery to regulatory approval.
    Lok AS; Zoulim F; Dusheiko G; Ghany MG
    J Hepatol; 2017 Oct; 67(4):847-861. PubMed ID: 28778687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
    Degasperi E; Viganò M; Aghemo A; Lampertico P; Colombo M
    Expert Rev Anti Infect Ther; 2013 May; 11(5):459-74. PubMed ID: 23627852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.